SMS Pharmaceuticals Ltd reported a 39% increase in net profit for FY25 compared to the previous year, with a revenue growth of 10% and a strong EBITDA margin of 18%. They also plan to invest ₹250 crore for capacity expansion and target a 20% revenue growth in FY26.